USA-based Puma Biotechnology (NYSE: PBYI) says that its Marketing Authorization Application (MAA) for neratinib has been validated by the European Medicines Agency (EMA).
Validation of the MAA confirms that the submission is complete and starts the EMA's formal review process. The potential indication for neratinib is for the extended adjuvant treatment of HER2-positive early stage breast cancer that has previously been treated with trastuzumab (Herceptin)-based adjuvant therapy. The MAA submission is based on the ExteNET Phase III study, which reached its primary endpoint whereby neratinib demonstrated a statistically-significant reduction of risk of invasive disease recurrence or death versus placebo.
Puma filed for European approval of neratinib in June this year and submitted a New Drug Application to the US Food and Drug Administration in July.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze